AbCellera Biologics vs OmniAb
ABCL and OABI side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABCL and OABI compare
AbCellera Biologics is the larger company, worth 4.6 times as much as OmniAb ($3.4B against $737M).
AbCellera Biologics grew revenue faster over the last twelve months (101% versus 90.6% for OmniAb).
OmniAb keeps more of each dollar of sales as profit, with a net margin of −108% compared with −249% at AbCellera Biologics.
OmniAb scores higher on the StockData Score (9 against 8 for AbCellera Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABCL | OABI |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $737M |
| Share price | $11.03 | $5.05 |
| Change, 1 year | 199% | 224% |
| Change, 5 years | −21.2% | −49.5% |
| Beta (5Y) | 2.11 | 1.68 |
| Employees | 562 | 107 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 51.1× | 18.3× (better) |
| P/B | 3.8× | 3.0× (better) |
| P/FCF | – | 309× |
| FCF yield | −3.5% | 0.32% (better) |
| Fair value | $4.06 | $3.71 |
| Margin of safety | −172% | −36.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 101% (better) | 90.6% |
| Revenue growth, 5Y average | −20.3% | – |
| Profitability | ||
| Operating margin | −340% | −116% (better) |
| Net margin | −249% | −108% (better) |
| FCF margin | −181% | 5.9% (better) |
| Return on equity | −17.3% | −16.5% (better) |
| Return on invested capital | −43.9% | −18.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.77 (better) | 4.21 |
| Altman Z-score | 4.85 | 9.48 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.9% | 42.4% |
| Held by insiders | 22.8% | 5.9% |
| Insider net buying, 12 months | $3.3M (better) | −$283K |
| Short interest, % of float | 12.3% | – |
Go deeper
- ABCL stock overview
- ABCL income statement
- ABCL valuation and score
- OABI stock overview
- OABI income statement
- OABI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.